It is possible that additional mechanisms downstream of PI3Kδ are responsible for the increased anti-tumour efficacy seen with PI3Kδ inhibition, and further studies should evaluate the role of other mechanisms in this process, including decreased LFA-1 activation, or the role of other AKT-independent PI3K functions and effectors. The gene discussed is AKT1; the disease is neoplasm.